QQQ   293.54 (+0.06%)
AAPL   148.25 (+0.15%)
MSFT   254.65 (-0.19%)
META   120.19 (+1.77%)
GOOGL   101.19 (+0.20%)
AMZN   95.59 (-0.98%)
TSLA   195.03 (+0.17%)
NVDA   171.72 (+1.47%)
NIO   12.25 (-4.15%)
BABA   86.13 (-1.63%)
AMD   77.02 (-0.79%)
T   19.13 (-0.78%)
MU   55.44 (-3.83%)
CGC   3.74 (+3.31%)
F   14.05 (+1.08%)
GE   85.63 (-0.40%)
DIS   97.90 (+0.03%)
AMC   8.67 (+19.92%)
PYPL   78.39 (-0.03%)
PFE   50.85 (+1.44%)
NFLX   316.89 (+3.72%)
QQQ   293.54 (+0.06%)
AAPL   148.25 (+0.15%)
MSFT   254.65 (-0.19%)
META   120.19 (+1.77%)
GOOGL   101.19 (+0.20%)
AMZN   95.59 (-0.98%)
TSLA   195.03 (+0.17%)
NVDA   171.72 (+1.47%)
NIO   12.25 (-4.15%)
BABA   86.13 (-1.63%)
AMD   77.02 (-0.79%)
T   19.13 (-0.78%)
MU   55.44 (-3.83%)
CGC   3.74 (+3.31%)
F   14.05 (+1.08%)
GE   85.63 (-0.40%)
DIS   97.90 (+0.03%)
AMC   8.67 (+19.92%)
PYPL   78.39 (-0.03%)
PFE   50.85 (+1.44%)
NFLX   316.89 (+3.72%)
QQQ   293.54 (+0.06%)
AAPL   148.25 (+0.15%)
MSFT   254.65 (-0.19%)
META   120.19 (+1.77%)
GOOGL   101.19 (+0.20%)
AMZN   95.59 (-0.98%)
TSLA   195.03 (+0.17%)
NVDA   171.72 (+1.47%)
NIO   12.25 (-4.15%)
BABA   86.13 (-1.63%)
AMD   77.02 (-0.79%)
T   19.13 (-0.78%)
MU   55.44 (-3.83%)
CGC   3.74 (+3.31%)
F   14.05 (+1.08%)
GE   85.63 (-0.40%)
DIS   97.90 (+0.03%)
AMC   8.67 (+19.92%)
PYPL   78.39 (-0.03%)
PFE   50.85 (+1.44%)
NFLX   316.89 (+3.72%)
QQQ   293.54 (+0.06%)
AAPL   148.25 (+0.15%)
MSFT   254.65 (-0.19%)
META   120.19 (+1.77%)
GOOGL   101.19 (+0.20%)
AMZN   95.59 (-0.98%)
TSLA   195.03 (+0.17%)
NVDA   171.72 (+1.47%)
NIO   12.25 (-4.15%)
BABA   86.13 (-1.63%)
AMD   77.02 (-0.79%)
T   19.13 (-0.78%)
MU   55.44 (-3.83%)
CGC   3.74 (+3.31%)
F   14.05 (+1.08%)
GE   85.63 (-0.40%)
DIS   97.90 (+0.03%)
AMC   8.67 (+19.92%)
PYPL   78.39 (-0.03%)
PFE   50.85 (+1.44%)
NFLX   316.89 (+3.72%)
NASDAQ:AMRS

Amyris - AMRS Stock Forecast, Price & News

$1.74
+0.02 (+0.87%)
(As of 12/1/2022 01:49 PM ET)
Add
Compare
Today's Range
$1.74
$1.86
50-Day Range
$1.52
$3.39
52-Week Range
$1.44
$6.96
Volume
185,227 shs
Average Volume
7.13 million shs
Market Capitalization
$568.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33

Amyris MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
206.5% Upside
$5.33 Price Target
Short Interest
Healthy
20.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Amyris in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$10.62 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.22) to ($0.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Basic Materials Sector

83rd out of 166 stocks

Industrial Organic Chemicals Industry

10th out of 20 stocks

AMRS stock logo

About Amyris (NASDAQ:AMRS) Stock

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

AMRS Stock News Headlines

Traders Buy Large Volume of Amyris Put Options (NASDAQ:AMRS)
Amyris (NASDAQ:AMRS) Trading Up 6.2%
Why Amyris Stock Was Driven Into the Ground on Wednesday
AMYRIS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
AMYRIS SUCCESSFULLY LAUNCHES TWO NEW CONSUMER BRANDS
Amyris Cost Breakdown (NASDAQ:AMRS) - Seeking Alpha
See More Headlines
Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

AMRS Company Calendar

Last Earnings
11/08/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Oil & Gas Refining & Marketing
Current Symbol
NASDAQ:AMRS
CUSIP
03236M10
Employees
980
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$5.33
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+205.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-270,970,000.00
Net Margins
-131.70%
Pretax Margin
-135.65%

Debt

Sales & Book Value

Annual Sales
$341.82 million
Book Value
($1.35) per share

Miscellaneous

Free Float
215,532,000
Market Cap
$568.14 million
Optionable
Optionable
Beta
1.22

Social Links


Key Executives

  • Mr. John G. MeloMr. John G. Melo (Age 56)
    Pres, CEO & Director
    Comp: $1.94M
  • Mr. Hermanus KieftenbeldMr. Hermanus Kieftenbeld (Age 56)
    CFO & Chief Admin. Officer
    Comp: $1.08M
  • Mr. Eduardo AlvarezMr. Eduardo Alvarez (Age 58)
    Chief Operating Officer
    Comp: $1.24M
  • Ms. Nicole KelseyMs. Nicole Kelsey (Age 55)
    Chief Legal Officer & Sec.
    Comp: $623.41k
  • Ms. Elizabeth E. Dreyer CPA (Age 60)
    Chief Accounting Officer & Corp. Controller
  • Mr. Peter DeNardo
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Christine Ofori
    Chief People Officer
  • Mr. Charles Kraft
    Sr. VP of Global Manufacturing & Process Devel.
  • Ms. Caroline Hadfield
    Pres of Aprinnova
  • Mr. Jim Iacoponi
    Sr. VP of Nutrition Ingredients













AMRS Stock - Frequently Asked Questions

Should I buy or sell Amyris stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings
or view top-rated stocks.

What is Amyris' stock price forecast for 2023?

4 Wall Street analysts have issued twelve-month price objectives for Amyris' stock. Their AMRS share price forecasts range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 208.3% from the stock's current price.
View analysts price targets for AMRS
or view top-rated stocks among Wall Street analysts.

How have AMRS shares performed in 2022?

Amyris' stock was trading at $5.41 on January 1st, 2022. Since then, AMRS stock has decreased by 68.0% and is now trading at $1.73.
View the best growth stocks for 2022 here
.

When is Amyris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AMRS earnings forecast
.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) announced its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $47.90 million during the quarter, compared to analyst estimates of $64.21 million. Amyris's quarterly revenue was up 39.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.41) EPS.

When did Amyris' stock split?

Amyris's stock reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What guidance has Amyris issued on next quarter's earnings?

Amyris updated its fourth quarter 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $100.00M-, compared to the consensus revenue estimate of $138.39 million.

What is John Melo's approval rating as Amyris' CEO?

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.09%), BlackRock Inc. (4.08%), Vivo Capital LLC (2.38%), Edmond DE Rothschild Holding S.A. (2.26%), State of Michigan Retirement System (2.22%) and Farallon Capital Management LLC (1.88%). Insiders that own company stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo, L John Doerr, Nicole Kelsey and Patrick Y Yang.
View institutional ownership trends
.

How do I buy shares of Amyris?

Shares of AMRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $1.73.

How much money does Amyris make?

Amyris (NASDAQ:AMRS) has a market capitalization of $563.25 million and generates $341.82 million in revenue each year. The biotechnology company earns $-270,970,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis.

How many employees does Amyris have?

The company employs 980 workers across the globe.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The official website for the company is amyris.com. The biotechnology company can be reached via phone at (510) 450-0761, via email at investor@amyris.com, or via fax at 510-225-2645.

This page (NASDAQ:AMRS) was last updated on 12/1/2022 by MarketBeat.com Staff